Nine million euros for innovative cancer therapy
Biotech start-up aims to reduce side effects and increase efficacy with new technology
Advertisement
NRW.BANK has invested EUR 3.5 million in the Dortmund-based biotechnology start-up iDEL Therapeutics via its venture capital fund NRW.Venture. The development bank's investment was part of a seed financing round in which the young company was able to raise a total of nine million euros. iDEL Therapeutics is developing an innovative method to increase the effectiveness of cancer therapies and reduce their side effects at the same time.
"iDEL Therapeutics' technology has the potential to improve cancer therapy - and thus the treatment of a disease that represents one of the greatest medical challenges facing our society," says Johanna Antonie Tjaden-Schulte, Member of the Managing Board of NRW.BANK. "As the development bank for North Rhine-Westphalia, we actively support the development of ideas and technologies that make our lives better. At the same time, our investments strengthen North Rhine-Westphalia as a life science location.
New approach for more targeted cancer therapies
iDEL Therapeutics' approach is a so-called drug delivery system. This is a biomedical technology area that deals with how active ingredients can be precisely transported to their target location in the body and released. The solution from iDEL Therapeutics specifically targets cancer cells and transports active substances directly into the cell interior. Healthy cells are spared. This reduces side effects and at the same time increases the effectiveness of cancer therapy.
The biotech start-up was founded in September 2025 and is based at the Biomedical Center Dortmund. With the capital from the current financing round, iDEL Therapeutics intends to further develop its technology in a targeted manner and create the conditions for a clinical evaluation.
In addition to NRW.Venture, Gründerfonds Ruhr and KHAN Technology Transfer Fund-II have participated in the financing round, which is led by BioMedVC as lead investor.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.